Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

Michael Byrne, Anna K. Nowak · Annals of Oncology · 2004 · 646 citations · Full text

Medicine, Oncology, Thoracic Oncology +9

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 458 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 424 citations

Medicine, Oncology, Pharmacotherapy +11

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dean A. Fennell, Keith M. Kerr, Paul E. Van Schil et al. · Annals of Oncology · 2015 · 420 citations · Full text

Medicine, Oncology, Surgery +14

Phase III Trial of Pemetrexed Plus Best Supportive Care Compared With Best Supportive Care in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma

Jacek Jassem, Rodryg Ramlau, Armando Santoro et al. · Journal of Clinical Oncology · 2008 · 231 citations · Full text

Medicine, Oncology, Pharmacology +17